Inquiry
Say hello, explore a clinical partnership, or ask about investment opportunities — we’d love to hear from you.
Please email contact@hemasense.com.
Your message has been received. We’ll be in touch shortly.
Early detection, accelerated recovery.
The Problem
Every year, hundreds of thousands of patients undergo life saving procedures that deliver therapy through a large diameter catheter in the the femoral artery or vein. Unfortunately, almost 1 in 10 patients will experience a clinically consequential bleed at this access site during recovery, often resulting in extended hospital stays, secondary surgeries, blood transfusions and significant cost increase to the healthcare system.
Access-site bleeding complication rate
Estimated annual direct cost
Additional hospital days per event
Average additional cost per event
Sources: LSI Market Analysis; JAMA Cardiol. 2017;2(7):798–802; Circulation 2022 Jan 18;145(3):170–183.
Technology
The HemaSense wearable access-site monitor provides real-time indications of a potential bleeding complication, supporting early detection and intervention.
The HemaSense device utilizes proven bioimpedance sensing technology combined with multi-model motion and signal-quality monitoring. Proprietary algorithms continuously analyze these signals to monitor for blood accumulation and differentiate meaningful tissue changes from movement and noise.
Disposable patch placed at the femoral access site following a large-bore intervention.
Assesses impedance changes during recovery that may be consistent with blood accumulation beneath the skin.
Highlights accumulation before they're palpable or visible, supporting earlier diagnosis and intervention.
Wireless communication, portable display with flexible mounting options.
Outcomes
By turning access-site recovery into a continuous, quantitative signal, HemaSense helps care teams act sooner — supporting better outcomes for patients and stronger economics for the hospital.
Bleeding complications increase mortality and morbidity and can lead to secondary surgeries and blood transfusions.
Potential complications are surfaced early, reducing severity.
Continuous, objective data without adding to staff workload.
Designed to support smoother recovery workflows and increase bed turnover, leading to greater efficiency.
A Paradigm Shift
Access-site monitoring currently relies on regular manual checks by frequently overloaded care teams, which can lead to inconsistent evaluations and delayed interventions.
Current Monitoring
With HemaSense
One signal, two advantages
When signal changes consistent with fluid accumulation appear, they are displayed in real time, supporting earlier assessment of a potential bleeding complication.
For the many patients recovering normally, continuous, objective readings give the team additional information to support confident recovery decisions.
The Opportunity
The intersection of expanding procedure volumes, increasingly complex patients, and a growing focus on healthcare efficiency is creating new demands for continuous post-procedural monitoring.
Large-bore procedures annually (2025)
Blended CAGR, 2025–2030
Projected annually by 2030
01
New structural heart, vascular, and electrophysiology therapies continue to drive significant growth in large-bore access, with many of the the newest devices using the largest catheters yet.
02
Older, sicker, and more complex patients are undergoing procedures that were once reserved for lower-risk populations.
03
Health systems are increasingly focused on reducing complications, shortening hospital stays, and improving operational efficiency.
Large-bore procedure volume by type
Thousands of procedures, 2025 vs. projected 2030
1000s of procedures (2025 / 2030). Source: LSI Market Analysis.
Traction
HemaSense has systematically reduced technical, clinical, regulatory, and market risk while advancing toward commercialization.
Technology
Clinical
Regulatory
Market
People
A team of medical-device operators, clinicians, and engineers who have designed, validated, and brought complex devices to market.
The latest
HemaSense closed an oversubscribed $630,000 pre-seed financing round backed by 19 individual angel investors. The round, combined with non-d...
Read more →
Nathan Friedman, CEO, shared the results of the first preclinical animal study of the HemaSense Device on the Innovation stage at TCT 2025....
Read more →HemaSense received $250,000 in funding through PEI’s WearTech Applied Research Center to support continued development of its wearable techn...
Read more →